Zhang Ye, Huth Isabel, Wegner Martin, Weber Damien C, Lomax Antony J
Center for Proton Therapy, Paul Scherrer Institut, Villigen-PSI, Switzerland. Varian Medical Systems-Particle Therapy GmbH, Troisdorf, Germany.
Phys Med Biol. 2017 May 21;62(10):4046-4061. doi: 10.1088/1361-6560/aa66c5. Epub 2017 Apr 20.
This simulation study investigated the dosimetric effectiveness and treatment efficiency of surface motion guided gating of pencil beam scanning (PBS) proton therapy for liver tumour treatments. Dedicated 4D dose calculations were performed for simulating gated treatments using 4DCT data for six patients derived from 4DMRI (4DCT(MRI)). Surface motion as a surrogate for tumour motion was extracted from the 4DMRI images and a linear internal-external correlation model applied to derive amplitude-based gating windows (GWs) of 10 and 5 mm. 4D treatments were simulated using gating and layered/volumetric rescanning (either alone or combined) and four assumed system latencies (50/100/200/500 ms) for the response time of the beam gating to the surrogate. Resulting 4D plans were compared using D5-D95 and V95 in the CTV as the primary metrics, as well as dose to the healthy liver and total treatment time. With no motion mitigation, interplay effects deteriorate the dose homogeneity by more than 30% with respect to the static reference plan, whereas with surface motion guided gating alone, this could be reduced to 12/20% and 5/10% (mean/max over all cases) for 10 mm and 5 mm GWs, respectively. Furthermore, by combining ×5 layered rescans with 5 mm GW, plan homogeneities to within 1/5% of the static references could be achieved. Dose inhomogeneities were however still pronounced for latencies ⩾200 ms but limited when ⩽100 ms. ITV volumes could be decreased by 19/25% when 10/5 mm GW was employed, leading to reductions in mean dose to the healthy liver tissue of 2.6/3.3%. Our results confirm the potential of combining gating and re-scanning (re-gating) for mitigating large tumor motions, and the potential of surface motion monitoring as a gating signal.
本模拟研究调查了表面运动引导的笔形束扫描(PBS)质子治疗用于肝脏肿瘤治疗的剂量学有效性和治疗效率。利用来自4D磁共振成像(4DCT(MRI))的6例患者的4DCT数据进行了专门的4D剂量计算,以模拟门控治疗。从4D MRI图像中提取表面运动作为肿瘤运动的替代指标,并应用线性内外相关模型得出基于幅度的10毫米和5毫米门控窗口(GWs)。使用门控和分层/体积重扫描(单独或组合)以及四种假定的系统延迟(50/100/200/500毫秒)模拟4D治疗,以反映束流门控对替代指标的响应时间。使用CTV中的D5-D95和V95作为主要指标,以及对健康肝脏的剂量和总治疗时间,对所得的4D计划进行比较。在没有运动缓解措施的情况下,与静态参考计划相比,相互作用效应使剂量均匀性恶化超过30%,而仅采用表面运动引导门控时,对于10毫米和5毫米的GWs,这一比例可分别降至12/20%和5/10%(所有病例的平均值/最大值)。此外,通过将×5分层重扫描与5毫米GW相结合,可实现与静态参考计划相差在1/5%以内的计划均匀性。然而,对于延迟⩾200毫秒,剂量不均匀性仍然很明显,但当⩽100毫秒时则受到限制。当采用10/5毫米GW时,ITV体积可减少19/25%,从而使健康肝组织的平均剂量降低2.6/3.3%。我们的结果证实了将门控和重新扫描(重新门控)相结合以减轻大肿瘤运动的潜力,以及将表面运动监测作为门控信号的潜力。